Determine the necessary mass, volume, or concentration for preparing a solution.
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
SKU | Size | Availability | Price | Qty |
---|---|---|---|---|
M126487-2mg | 2mg | In stock | $85.90 | |
M126487-5mg | 5mg | In stock | $177.90 | |
M126487-10mg | 10mg | In stock | $300.90 | |
M126487-25mg | 25mg | In stock | $677.90 | |
M126487-50mg | 50mg | In stock | $959.90 | |
M126487-100mg | 100mg | In stock | $1,728.90 | |
M126487-250mg | 250mg | In stock | $3,888.90 |
Synonyms | 2-(5-(3-(DIMETHYLAMINO)PROPYL)-2-METHYLPYRIDIN-3-YLAMINO)-9-(TRIFLUOROMETHYL)-5H-BENZO[B]PYRIMIDO[4,5-D]AZEPINE-6(7H)-THIONE | 2-[[5-[3-(dimethylamino)propyl]-2-methylpyridin-3-yl]amino]-9-(trifluoromethyl)-5,7-dihydropyrimido[5,4-d][1]benzazepine-6-thion |
---|---|
Specifications & Purity | Moligand™, ≥97% |
Biochemical and Physiological Mechanisms | MLN0905, a small-molecule PLK1 inhibitor, induces antitumor responses in human models of diffuse large B-cell lymphoma. PLK1 inhibition leads to pharmacodynamic pHisH3 modulation and significant antitumor activity in multiple DLBCL models |
Storage Temp | Store at -20°C |
Shipped In | Ice chest + Ice pads |
Grade | Moligand™ |
Action Type | INHIBITOR |
Mechanism of action | Inhibitor of polo like kinase 1 |
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Pubchem Sid | 488201272 |
---|---|
Pubchem Sid Url | https://pubchem.ncbi.nlm.nih.gov/substance/488201272 |
IUPAC Name | 2-[[5-[3-(dimethylamino)propyl]-2-methylpyridin-3-yl]amino]-9-(trifluoromethyl)-5,7-dihydropyrimido[5,4-d][1]benzazepine-6-thione |
INCHI | InChI=1S/C24H25F3N6S/c1-14-19(9-15(12-28-14)5-4-8-33(2)3)31-23-29-13-16-10-21(34)30-20-11-17(24(25,26)27)6-7-18(20)22(16)32-23/h6-7,9,11-13H,4-5,8,10H2,1-3H3,(H,30,34)(H,29,31,32) |
InChi Key | CODBZFJPKJDNDT-UHFFFAOYSA-N |
Canonical SMILES | CC1=C(C=C(C=N1)CCCN(C)C)NC2=NC=C3CC(=S)NC4=C(C3=N2)C=CC(=C4)C(F)(F)F |
Isomeric SMILES | CC1=C(C=C(C=N1)CCCN(C)C)NC2=NC=C3CC(=S)NC4=C(C3=N2)C=CC(=C4)C(F)(F)F |
PubChem CID | 46235922 |
Molecular Weight | 486.56 |
PubChem CID | 46235922 |
---|---|
CAS Registry No. | 1228960-69-7 |
ChEMBL Ligand | CHEMBL1945805 |
PubChem SID | 488201272 |
Enter Lot Number to search for COA:
Find and download the COA for your product by matching the lot number on the packaging.
Lot Number | Certificate Type | Date | Item |
---|---|---|---|
K2322393 | Certificate of Analysis | Aug 21, 2023 | M126487 |
K2322392 | Certificate of Analysis | Aug 21, 2023 | M126487 |
K2322391 | Certificate of Analysis | Aug 21, 2023 | M126487 |
K2322390 | Certificate of Analysis | Aug 21, 2023 | M126487 |
F2307498 | Certificate of Analysis | May 08, 2023 | M126487 |
F2308093 | Certificate of Analysis | May 08, 2023 | M126487 |
F2308092 | Certificate of Analysis | May 08, 2023 | M126487 |
F2308089 | Certificate of Analysis | May 08, 2023 | M126487 |
F2308088 | Certificate of Analysis | May 08, 2023 | M126487 |
F2307488 | Certificate of Analysis | May 08, 2023 | M126487 |
F2307497 | Certificate of Analysis | May 08, 2023 | M126487 |
F2307496 | Certificate of Analysis | May 08, 2023 | M126487 |
F2307495 | Certificate of Analysis | May 08, 2023 | M126487 |
F2307494 | Certificate of Analysis | May 08, 2023 | M126487 |
F2307493 | Certificate of Analysis | May 08, 2023 | M126487 |
F2307492 | Certificate of Analysis | May 08, 2023 | M126487 |
F2307491 | Certificate of Analysis | May 08, 2023 | M126487 |
F2307490 | Certificate of Analysis | May 08, 2023 | M126487 |
1. Duffey MO, Vos TJ, Adams R, Alley J, Anthony J, Barrett C, Bharathan I, Bowman D, Bump NJ, Chau R et al.. (2012) Discovery of a potent and orally bioavailable benzolactam-derived inhibitor of Polo-like kinase 1 (MLN0905).. J Med Chem, 55 (1): (197-208). [PMID:22070629] [10.1021/op500134e] |